Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
Sponsor: Arriva Pharmaceuticals, Inc.
A PHASE1/PHASE2 clinical study on Alpha1-antitrypsin Deficiency, this trial is completed. The trial is conducted by Arriva Pharmaceuticals, Inc. and has accumulated 8 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE1_PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1_PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Nov 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Jan 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arriva Pharmaceuticals, Inc.
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .